TDH: One-shot Johnson & Johnson COVID vaccine moving forward

After an extensive analysis of the risks and benefits of the Janssen/Johnson & Johnson COVID-19 vaccine, the Advisory Committee on Immunization Practices voted Friday to recommend to the Centers for Disease Control and Prevention that jurisdictions may resume their administration of the Janssen/Johnson & Johnson vaccine without restrictions.

The committee made the determination after reviewing cases of rare but serious blood clots occurring in some individuals who received the vaccine. To date, 15 cases have been reported with the majority occurring in women ages 18-49 years. The risk of developing the condition is approximately 7 in 1 million vaccine doses for women in that age group. For women ages 50 years and older and for men, the risk is approximately 1 in 1 million vaccine doses.

The Tennessee Department of Health is taking necessary steps to inform all approved COVID-19 vaccine providers across the state of the information released by ACIP so that they may resume the administration of the Janssen/Johnson & Johnson vaccine as soon as possible. While the Janssen/Johnson & Johnson vaccine is in short supply, most vaccine providers in Tennessee continue to have abundant supply of the Pfizer and Moderna vaccines.

Women between the ages of 18 and 49 years should weigh the risk of the vaccine with its benefits when deciding to receive the Janssen/Johnson & Johnson vaccine versus the mRNA vaccines from Pfizer and Moderna, which have not been associated with this rare blood clotting disorder.

Individuals seeking a COVID-19 vaccine appointment can visit COVID19.tn.gov or vaccinefinder.org to schedule an appointment with a local vaccine provider.